News coverage about Vertex Pharmaceuticals (NASDAQ:VRTX) has been trending somewhat positive recently, according to Accern Sentiment. The research firm identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Vertex Pharmaceuticals earned a media sentiment score of 0.23 on Accern’s scale. Accern also gave headlines about the pharmaceutical company an impact score of 45.6966268074944 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the media stories that may have effected Accern’s rankings:
- Global Respiratory Drugs (Pharmacuticals / Healthcare) Market 2018-2024 – ResearchAndMarkets.com (oaoa.com)
- What Irrational Exuberance Behind the Bloomin’ Brands, Inc. (BLMN) and Vertex Pharmaceuticals Incorporated (VRTX)? (nmsunews.com)
- $674.90 Million in Sales Expected for Vertex Pharmaceuticals (VRTX) This Quarter (americanbankingnews.com)
- Vertex Pharmaceuticals (VRTX) EVP Sells $21,497.64 in Stock (americanbankingnews.com)
- Vertex Pharmaceuticals (VRTX) COO Sells $33,804.26 in Stock (americanbankingnews.com)
A number of brokerages have issued reports on VRTX. Barclays increased their target price on shares of Vertex Pharmaceuticals from $180.00 to $200.00 and gave the stock an “overweight” rating in a research report on Thursday, February 1st. TheStreet upgraded shares of Vertex Pharmaceuticals from a “c+” rating to a “b-” rating in a research report on Friday, March 2nd. HC Wainwright restated a “hold” rating and set a $103.00 target price on shares of Vertex Pharmaceuticals in a research report on Thursday, February 1st. Zacks Investment Research lowered shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Sunday, January 21st. Finally, BidaskClub lowered shares of Vertex Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Wednesday, May 9th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and twenty-six have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $184.54.
Shares of Vertex Pharmaceuticals traded up $0.90, reaching $157.24, on Friday, Marketbeat Ratings reports. 998,525 shares of the stock were exchanged, compared to its average volume of 1,698,350. Vertex Pharmaceuticals has a one year low of $115.10 and a one year high of $178.25. The company has a current ratio of 3.68, a quick ratio of 3.53 and a debt-to-equity ratio of 0.01. The company has a market cap of $39.79 billion, a PE ratio of 196.55, a price-to-earnings-growth ratio of 1.91 and a beta of 1.44.
Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings data on Thursday, April 26th. The pharmaceutical company reported $0.76 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.63 by $0.13. The business had revenue of $641.00 million during the quarter, compared to the consensus estimate of $626.05 million. Vertex Pharmaceuticals had a net margin of 9.36% and a return on equity of 15.28%. The firm’s revenue was down 10.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.99 EPS. research analysts forecast that Vertex Pharmaceuticals will post 1.95 earnings per share for the current year.
Vertex Pharmaceuticals declared that its Board of Directors has approved a stock buyback plan on Wednesday, January 31st that authorizes the company to repurchase $500.00 million in shares. This repurchase authorization authorizes the pharmaceutical company to buy shares of its stock through open market purchases. Shares repurchase plans are generally an indication that the company’s board of directors believes its shares are undervalued.
In related news, COO Ian F. Smith sold 85,093 shares of the stock in a transaction that occurred on Thursday, April 26th. The shares were sold at an average price of $158.32, for a total value of $13,471,923.76. Following the completion of the transaction, the chief operating officer now owns 68,745 shares of the company’s stock, valued at approximately $10,883,708.40. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Michael Parini sold 2,330 shares of the stock in a transaction that occurred on Thursday, May 3rd. The shares were sold at an average price of $149.50, for a total transaction of $348,335.00. Following the completion of the transaction, the executive vice president now directly owns 41,939 shares of the company’s stock, valued at approximately $6,269,880.50. The disclosure for this sale can be found here. In the last three months, insiders sold 172,907 shares of company stock valued at $27,820,874. 1.80% of the stock is owned by insiders.
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated, a biotechnology company, develops medicines for serious diseases. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI (lumacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are homozygous for the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; KALYDECO (ivacaftor) for the treatment of patients with CF who have specific mutations in their CFTR gene, including the G551D mutation; and SYMDEKO (tezacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are F508del homozygous or who have 1 mutation that is responsive to tezacaftor/ivacaftor.
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.